Earendil Labs secured a $1.5 billion discovery collaboration with Genentech to develop bispecific antibody therapeutics in oncology. The agreement is Earendil’s second major partnership in 2026 and positions the startup’s AI-led platform as a continued pipeline source for Roche’s antibody strategy. The deal underscores corporate preference for early-stage discovery partnerships that can deliver multiple candidates across an extended milestone timeline, rather than single-target licensing. For the industry, the transaction is another data point that antibody engineering platforms—especially those combining model-guided design with experimental validation—remain attractive to Big Pharma despite market volatility. As bispecifics continue to expand beyond hematology, these large collaborations aim to sustain oncology innovation while managing risk across discovery programs.